Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Eighteen consecutive patients with measurable locally advanced or metastatic pancreatic adenocarcinoma were treated with goserelin (Zoladex) 3.6 mg subcutaneously every 4 weeks. Hydrocortisone 20 milligrams twice daily was commenced with the second injection of goserelin. Objective tumour response was monitored by computerised tomography of the abdomen. There was no objective remission in disease sites. Serial measurements of serum tumour markers showed no reduction in serum CA 19-9 and CA 195 concentrations. The median duration of survival of all cases was 5 months. Administration of goserelin resulted in significant reductions in oestradiol, testosterone, androstenedione in males and reductions in FSH and LH in both males and females. The addition of hydrocortisone resulted in further reductions of androstenedione and testosterone levels in males. Thus goserelin showed no anti-tumour effect, but concentrations required for direct inhibitory effects may be higher than those required to produce effects on hormone suppression.

Original publication

DOI

10.1038/bjc.1993.69

Type

Journal article

Journal

Br J Cancer

Publication Date

02/1993

Volume

67

Pages

379 - 382

Keywords

Adenocarcinoma, Adult, Aged, Androgens, Androstenedione, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Estradiol, Female, Follicle Stimulating Hormone, Goserelin, Humans, Hydrocortisone, Luteinizing Hormone, Male, Middle Aged, Pancreatic Neoplasms, Testosterone